BioNTech and Pfizer Climb After Covid-19 Vaccine Wins U.K. Authorization
December 02 2020 - 1:53PM
Dow Jones News
By Maria Armental
BioNTech SE trades near record levels following U.K. health
regulator's emergency-use authorization for a Covid-19 vaccine
developed by the German company and Pfizer Inc.
The approval clears the way for the two-shot vaccine to be
distributed in limited numbers in the U.K. within days.
BioNTech shares, which traded as high as $123.59 on Wednesday,
recently traded at $121.23, up 6% for the day and near the $124.24
closing record set on Nov. 30, according to FactSet.
Pfizer, meanwhile, traded 3.5% higher at $40.78.
A panel of experts advising the Food and Drug Administration is
slated to review the vaccine on Dec. 10. The FDA could authorize
soon after, and supplies should become available not long after
that. Pfizer has already started shipping shots to distribution
sites.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
December 02, 2020 13:38 ET (18:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024